The World Health Organization has released new guidelines for the treatment of malaria, and the first ever guidance on procuring safe and efficacious anti-malarial medicines. In recent years, the WHO points out, a new type of treatment - artemisinin-based combination therapy (ACTs) - has transformed the treatment of malaria, but warns that, if not used properly the medicine could become ineffective.
The Guidelines for the Treatment of Malaria (second edition) provides evidence-based and current recommendations for countries on malaria diagnosis and treatment. The main changes from the first edition of the guidelines (published in 2006) are the emphasis on testing before treating and the addition of a new ACT to the list of recommended treatments.
Stresses need for diagnostic testing
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze